The positive pivotal readout de-risks the regulatory pathway and supports the De Novo submission timeline. Key catalysts to watch: FDA acceptance of the De Novo application (late Q4 2026), 12-month co-primary endpoint data (Q1 2027), and any FDA feedback on the complete safety dataset. Monitor for potential partnership or financing updates given the pre-commercial stage.
Price Chart
Executive Summary
Fractyl Health reported positive topline six-month results from the REMAIN-1 pivotal study of its Revita DMR System for post-GLP-1 weight maintenance. The study met its first co-primary endpoint with high statistical significance (p=0.0023), showing Revita participants retained ~80% of GLP-1-induced weight loss vs 67% for sham. The company plans a De Novo FDA submission in late Q4 2026 and expects 12-month data in Q1 2027.
Key Facts
- Six-month co-primary endpoint met: Revita participants maintained ~80% of GLP-1-induced weight loss vs 67% for sham (p=0.0023)
- Least-squares mean weight regain: 5.1% for Revita vs 8.2% for sham (n=176 vs 74)
- 32% of Revita participants were weight stable or had further weight loss vs 18% for sham (post hoc, nominal p=0.020)
- Dose-dependent effect: participants with ≥20 cm ablation had 53% less regain than sham (mean regain 3.8% vs 8.2%; nominal p=0.003)
- No device- or procedure-related serious adverse events, no deaths, no unanticipated adverse device effects
- De Novo marketing application submission to FDA planned for late Q4 2026
- Topline 12-month data and second co-primary endpoint expected Q1 2027
- Category III CPT code 1122T for Revita procedure takes effect January 1, 2027
- Potential U.S. commercial launch expected early 2028
- FDA Breakthrough Device Designation for post-GLP-1 weight maintenance
Financial Impact
No revenue or financial data reported; company is pre-commercial. Filing states estimated price per procedure of $11,000-$33,000 and ~80% gross margin at scale, with cash breakeven projected within 5-8 quarters of launch.
Risk Factors
- FDA may not accept the De Novo application or may require additional clinical data
- 12-month co-primary endpoint may not meet the pre-specified performance goal of >50%
- Commercial adoption depends on reimbursement, physician training, and competition from GLP-1 drugs
- Company is pre-revenue with no disclosed cash runway; may require additional financing
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-423377 |
| Document: guts-ex99_2.htm | 0001193125-26-423377 |
| Document: guts-ex99_1.htm | 0001193125-26-423377 |
| Document: 0001193125-26-423377-index-headers.html | 0001193125-26-423377 |
| Document: 0001193125-26-423377-index.html | 0001193125-26-423377 |
| Document: 0001193125-26-423377.txt | 0001193125-26-423377 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $1.13 | awaiting T+5 | — | $1.08 (−4.42%) |
Oct 16, 2026 10d ago | 8-K | $1.55 $1.08 | ▼ −30.32% | ▼ −30.42% | $1.08 (−30.32%) |
Oct 13, 2026 12d ago | SC 13G | $4.03 $1.33 | ▼ −66.96% | ▼ −65.80% | $1.08 (−73.17%) |
Aug 10, 2026 10w ago | 8-K | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Aug 10, 2026 10w ago | Press Release | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Jul 15, 2026 14w ago | 8-K | $0.9100 $0.7580 | ▼ −16.70% | ▼ −15.72% | $1.08 (+18.68%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Insider Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.99% | $1.08 (+49.19%) |
Jun 4, 2026 20w ago | 8-K | $0.7340 $0.7240 | ▼ −1.36% | ▲ +1.19% | $1.08 (+47.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers